LMCA Treatment Outcome

Launched by CHINESE UNIVERSITY OF HONG KONG · May 22, 2024

Keywords

ClinConnect Summary

The LMCA Treatment Outcome trial is studying how effective different treatments are for patients with significant disease in the left main coronary artery, which is a crucial blood vessel supplying the heart. The trial is particularly focused on patients who have been on a waiting list for surgery (coronary artery bypass grafting, or CABG) from January 2000 to December 2020. It aims to understand the outcomes of these patients while they are receiving modern medical treatments, such as medications to lower cholesterol and prevent blood clots, during their waiting period.

To be eligible for this trial, patients must have significant disease in their left main coronary artery and must have been referred for CABG by a specialized HEART team. However, those with other serious heart valve problems or those needing urgent surgery are not included. Participants in the trial can expect to have their health monitored and to receive guidance on their treatment options while they wait for surgery. This study is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with significant LMCA disease who were on the waitlist for CABG since 1st January 2000 to 31st December 2020.
• • The decision for CABG over PCI as a mode of revascularization for the patients on this waitlist were collectively made by the HEART team
• Exclusion Criteria:
• • patients with co-existing significant valvular heart disease requiring concomitant surgical intervention, and unstable patients in whom urgent surgical intervention was performed